Loading the company…
Loading the company…
Listed on the SIX Swiss Exchange; no SEC filings. Families: Lumbar fusion, Cervical fusion & disc arthroplasty, SI joint fusion.
All companies · Product and company coverage
In 2025, Medacta reported engagement with 892 surgeons and other clinicians in the states MedaRep covers, worth $4.4M in consulting, speaking, meals and travel for its device products, the most in California ($1.1M to 70). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($1.1M, 70 engaged), Kentucky ($377K, 31 engaged), Pennsylvania ($289K, 48 engaged), Texas ($273K, 74 engaged), Washington ($251K, 9 engaged).
In the last ten years FDA made 123 decisions for Medacta (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 3 procedure families, the most in 2020 (21). The latest was on 2026-09-17.
| Family | Decisions on record |
|---|---|
| Lumbar fusion | 33 |
| Cervical fusion & disc arthroplasty | 13 |
| SI joint fusion | 3 |
| MectaLIF 3D Metal Anterior |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Medacta.